Demand Spurs Efforts to Improve Recruitment, Retention

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

Focus groups, mentoring, and expanded recruitment efforts have helped Roswell Park Cancer Institute (RPCI) keep its vacancy rate low in the midst of a nursing shortage

BOSTON—Focus groups, mentoring, and expanded recruitment efforts have helped Roswell Park Cancer Institute (RPCI) keep its vacancy rate low in the midst of a nursing shortage, said Denise Rutkowski, MS, RN, CRC, OCN, nurse recruiter and retention coordinator at RPCI. "The average age of our nurses is 44. Our average length of service is about 11 years. Our current vacancy rate is 6.5%, compared to 20% nationally," Ms. Rutkowski said at the Oncology Nursing Society 31st Annual Congress (abstract 284).

To increase retention, focus groups are held with new nurses and the Human Resources Department, to determine why the nurses selected RPCI, which factors helped them become acclimated to their new position, and what needs to be changed to help with the next round of orientation. In addition, Roswell Park connects new nurses with mentors.

Roswell Park is beginning to focus its recruitment efforts not only on the Western New York region but across the country, to attract nurses who have family in this region or wish to relocate. "We believe we can offer oncology nurses a dynamic work environment and one in which they can be professionally satisfied," Ms. Rutkowski concluded.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content